Arrowstreet Capital
ACAD icon

Arrowstreet Capital’s Acadia Pharmaceuticals ACAD Stock Holding History

Arrowstreet Capital’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$49.8M Buy
1,969,445
+399,954
+25% +$8.8M 0.02% 566
2026
Q1 		$34.9M Buy
1,569,491
+66,874
+4% +$1.6M 0.02% 595
2025
Q4 		$40.1M Sell
1,502,617
-146,247
-9% -$3.49M 0.02% 538
2025
Q3 		$35.2M Buy
1,648,864
+1,312,426
+390% +$31M 0.02% 559
2025
Q2 		$7.26M Buy
+336,438
New +$6.25M 0.01% 1012
2023
Q4 		– Sell
-54,901
Closed -$1.14M – 1383
2023
Q3 		$1.14M Buy
+54,901
New +$1.49M ﹤0.01% 955
2022
Q3 		– Sell
-61,099
Closed -$861K – 1246
2022
Q2 		$861K Buy
+61,099
New +$1.14M ﹤0.01% 966
2021
Q1 		– Sell
-6,100
Closed -$326K – 2203
2020
Q4 		$326K Sell
6,100
-137,661
-96% -$6.83M ﹤0.01% 2103
2020
Q3 		$5.93M Sell
143,761
-142,373
-50% -$6.15M 0.01% 1080
2020
Q2 		$13.9M Buy
286,134
+253,134
+767% +$12.2M 0.03% 647
2020
Q1 		$1.39M Sell
33,000
-614,248
-95% -$25.3M ﹤0.01% 1195
2019
Q4 		$27.7M Buy
+647,248
New +$28.2M 0.06% 309

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Arrowstreet Capital's ACAD Position: Q2 2026 in Review

Arrowstreet Capital increased its Acadia Pharmaceuticals (ACAD) stake by 25% in Q2 2026, buying an estimated $8.8M and bringing the position to 1,969,445 shares worth $49.8M. The position accounts for 0.02% of the portfolio, ranked #566.

Arrowstreet Capital first reported a position in ACAD in Q4 2019 and has held it in 12 quarters since. 354 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Arrowstreet Capital held 1,969,445 shares of Acadia Pharmaceuticals worth $49.8M as of Q2 2026.
  • Arrowstreet Capital bought 399,954 Acadia Pharmaceuticals shares in Q2 2026, an estimated $8.8M.
  • Acadia Pharmaceuticals made up 0.02% of Arrowstreet Capital's portfolio in Q2 2026, its #566 holding.
  • Arrowstreet Capital first reported a position in Acadia Pharmaceuticals in Q4 2019 and has held it in 12 quarters since.
  • 354 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Arrowstreet Capital's 13F filing for Q2 2026, filed 13 Aug 2026.